KN-93
Catalog No.: GC10629Purity:>99.50%
KN-93 is an effective, cell-membrane permeable, and selective inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with an IC50 value of 0.37μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 139298-40-1
10mM (in 1mL DMSO)In Stock
$85.00
1
1mgIn Stock
$39.00
1
5mgIn Stock
$77.00
1
10mgIn Stock
$107.00
1
25mgIn Stock
$234.00
1
50mgIn Stock
$402.00
1
| Pack Size | Price | Availability | Quantity | Action |
|---|---|---|---|---|
| 10mM (in 1mL DMSO) | $85.00 | In Stock | 1 | |
| 1mg | $39.00 | In Stock | 1 | |
| 5mg | $77.00 | In Stock | 1 | |
| 10mg | $107.00 | In Stock | 1 | |
| 25mg | $234.00 | In Stock | 1 | |
| 50mg | $402.00 | In Stock | 1 |
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com
Citations
3 publicationsPublications from researchers using this productDescription
KN-93 is an effective, cell-membrane permeable, and selective inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with an IC50 value of 0.37μM[1, 2]. KN-93 inhibits the rapid component of the delayed rectifier potassium current (IKr) in mammalian cardiomyocytes[3]. KN-93 induces nuclear translocation of histone deacetylase 4 (HDAC4), thereby promoting fatty acid oxidation in myocardial infarction[4].
In vitro, treatment of LX-2 human hepatic stellate cells with KN-93 (0-50μM) for 24h decreased cell viability and the expression of cell cycle regulatory proteins p53 and p21 in a dose-dependent manner[5]. Treatment of NMDA-induced neuronal cells with KN-93 (1μM) significantly reduced cell apoptosis, LDH release, and intracellular calcium concentration[6].
In vivo, 21-day treatment of Parkinson's disease rats with KN-93 (2μg, 5μg) via striatal injection significantly alleviated levodopa-induced motor dysfunction, reduced phosphorylation levels of GluR1 in the nucleus accumbens, and decreased the expression levels of glutamate decarboxylase 1 (Gad1) and Nur77 (NR4A1, an orphan receptor of the nuclear receptor superfamily)[7].
References:
[1] Anderson M E, Braun A P, Wu Y, et al. KN-93, an inhibitor of multifunctional Ca++/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart[J]. The Journal of pharmacology and experimental therapeutics, 1998, 287(3): 996-1006.
[2] Agulló L, Garcia-Dorado D, Escalona N, et al. Membrane association of nitric oxide-sensitive guanylyl cyclase in cardiomyocytes[J]. Cardiovascular research, 2005, 68(1): 65-74.
[3] Hegyi B, Chen-Izu Y, Jian Z, et al. KN-93 inhibits IKr in mammalian cardiomyocytes[J]. Journal of Molecular and Cellular Cardiology, 2015, 89: 173-176.
[4] Zhao J, Li L, Wang X, et al. KN-93 promotes HDAC4 nucleus translocation to promote fatty acid oxidation in myocardial infarction[J]. Experimental Cell Research, 2024, 438(2): 114050.
[5] An P, Zhu J Y, Yang Y, et al. KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro[J]. World Journal of Gastroenterology: WJG, 2007, 13(9): 1445.
[6] Liu X, Ma C, Xing R, et al. The calmodulin-dependent protein kinase II inhibitor KN-93 protects rat cerebral cortical neurons from N-methyl-D-aspartic acid-induced injury☆[J]. Neural Regeneration Research, 2013, 8(2): 111-120.
[7] Yang X, Wu N, Song L, et al. Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson’s disease[J]. Neuropsychiatric disease and treatment, 2013: 1213-1220.
Protocol
| Cell experiment [1]: | |
|
Cell lines |
LX-2 cells |
|
Preparation Method |
LX-2 cells were incubated with 0, 5, 10, 25, 50μM of KN-93 for 24h, and cell viability was then measured using the CCK-8 assay. |
|
Reaction Conditions |
0, 5, 10, 25, 50μM; 24h |
|
Applications |
After incubation of KN-93 at various concentrations for 24h, the number of LX-2 cells reduced dramatically from 81.76% (5μM) to 27.15% (50μM). |
| Animal experiment [2]: | |
|
Animal models |
Sprague Dawley rats |
|
Preparation Method |
6-hydroxydopamine (OHDA) injections were used to create a rat model of Parkinson's disease (PD). After 3 weeks of injections, rats exhibiting stable apomorphine-induced rotations (≥0.7 turns/minute) were selected as valid PD rats. Forty of these PD rats were treated with levodopa plus benserazide twice daily for 21 days. Abnormal involuntary movement (AIM) scores were measured on days 1, 7, 14, and 21 of treatment. In addition, one group of PD rats (PD group, n=10) and another group of sham-operated rats (sham group, n=10) were treated with vehicle twice daily for 21 days. On day 22, the 40 levodopa-treated PD rats were randomly divided into four groups: levodopa+KN-93 (1µg) group, levodopa+KN-93 (2µg) group, levodoap+KN-93 (5µg) group, and levodopa+vehicle group. These rats received intrastriatal injections of different doses of KN-93 (1µg, 2µg, or 5µg) or vehicle before levodopa treatment. As a control, the sham group and PD group rats received intrastriatal injections of vehicle before vehicle treatment. Apomorphine-induced rotations were measured to assess the antiparkinsonian effect of KN-93 on days 1 and 22. AIM scores were measured to assess the antidyskinetic effect of KN-93 on days 1, 7, 14, 21, and 22. At the end of the experiment, rats were euthanized with deep anesthesia using 3% phenobarbital. Western blot analysis was used to determine the levels of GluR1 and pGluR1S845. Real-time polymerase chain reaction (PCR) was used to measure the levels of Gad1 and Nurr77. |
|
Dosage form |
1, 2, 5μg; 21 days; intrastriatally treated |
|
Applications |
2µg and 5µg KN-93 treatment lowered AIMs scores in levodopa priming PD rats without affecting the antiparkinsonian effect of levodopa. In agreement with behavioral analysis, KN-93 treatment reduced pGluR1S845 levels in PD rats. Moreover, KN-93 treatment reduced the expression of Gad1 and Nur77 in PD rats. |
|
References: |
|
Product Documents
Purity:>99.50%Appearance:A solid
Chemical Properties
CAS No.
139298-40-1
Chemical Name
N-[2-[[[(E)-3-(4-chlorophenyl)prop-2-enyl]-methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide
SMILES
CN(CC=CC1=CC=C(C=C1)Cl)CC2=CC=CC=C2N(CCO)S(=O)(=O)C3=CC=C(C=C3)OC
Molecular Formula
C26H29ClN2O4S
Molecular Weight
501.04
Solubility
≥ 19.15mg/mL in DMSO
Storage
Store at -20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.
CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility
g/mol
Reviews
Review for KN-93
Rating: 5
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%